Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRichard Fatica

About this trial

This is a 16 week pilot study of the impact of a nutritionist led ketogenic diet (Ren-Nu) supplemented with the medical food KetoCitra on autosomal dominant polycystic kidney disease.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult (18 years or older)

Diagnosis of ADPKD by a physician.

Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2 at screening using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

Appropriate control of blood pressure (i.e. entry reading <140/90) including the use of BP medications for diagnosis of hypertension.

Disqualifiers

Intolerance or allergy to any of the ingredients in the provided medical food

History of hyperkalemia

Heart failure

Liver cirrhosis

Trial design

Design model

Single group

Treatments tested in this trial

  • Ren-Nu and KetoCitra

    Dietary supplement

    This is a structured, nutritionist monitored program supplemented with a nutritional food product, while monitoring metabolic parameters

Treatment groups

20 Participants
are divided into 1 treatment group
Group A: Pilot study on ketogenic diet Ren-Nu and KetoCitra supplement on ADPKDExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in Serum Renal Function

Change from baseline of renal function assessment as measured by creatinine based estimated glomerular filtration rate.

Time frame
Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
2

Change in Serum Hepatic Function Biomarkers

Change from baseline of serum liver panel biomarkers to track safety signals. Biomarkers include: AST (U/L), ALT (U/L), and LDH (U/L). Measured via standard clinical laboratory assays.

Time frame
Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
3

Change in Glycemic Control

Change from baseline of glycemic control as measured by aggregate of Hgb A1c and Homeostatic model assessment of insulin resistance (HOMA-IR).

Time frame
Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
4

Change in Systemic Inflammation Markers

Change from baseline of inflammatory biomarkers as an aggregate using: serum C-reactive protein \[(CRP) mg/dL\] and homocysteine (umol/L). Measured via standard clinical laboratory assays.

Time frame
Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu

Secondary outcomes

1

Change in health-related quality of life as assessed by the Quality of Life: Short-Form Health Survey 12 (SF-12v2)

Participants will complete the Quality of Life: Short-Form Health Survey 12 (SF-12v2) on Day 0 and Day 120. Scores are standardized by mean. A higher score indicates a better-than-average health-related quality of life, while a lower score suggests a below-average health-related quality of life.

Time frame
Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
2

Change in self reported mental and physical health outcomes

This is reported as a change in participant reported mental health status measured via both the Quality of Life: Short-Form Health Survey 12 (SF-12v2) and the study-developed Ren-Nu Outcomes survey. The outcomes survey assesses topics such as final weight (kg), final blood pressure (mmHg), current PKD related symptoms, and changes to medications/supplements.

Time frame
Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
3

Assessment of nutrition knowledge following the structured nutrition education program

Self reported participant nutrition knowledge of the nutritional program at the end of the program. This is a study-developed questionnaire and these questions are multiple choice with a low score reflecting lower nutritional knowledge of the dietary program and a high score reflecting higher nutritional knowledge of the dietary program.

Time frame
Visit 3 (Day 120) after Ren-Nu
4

Assessment of dietary intervention tolerability following the structured nutrition education program

Self reported participant tolerability of the nutritional program at the end of the program. This is a study-developed questionnaire and questions are multiple choice with a low score reflecting a lower tolerability to the dietary program and a high score reflecting higher satisfaction with the program.

Time frame
Visit 3 (Day 120) after Ren-Nu

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Richard Fatica

Lead sponsor

The Cleveland Clinic

Sponsor institution

Santa Barbara Nutrients

Collaborator